References
- Li J, Huang B, Li Y, et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 2015;56:1710–1717.
- Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699–712.
- Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269–1280.
- Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J 2014;11:22.
- Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575–3583.
- Nencioni A, Schwarzenberg K, Brauer KM, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006;108:551–558.
- World Health Organization. Hepatitis B fact sheet number 204. Geneva: WHO; 2008.
- Becker N, Schnitzler P, Boffetta P, et al. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol 2012;138:1993–2001.
- Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia-an Asian Myeloma Network study. Am J Hematol 2014; 89:751–756.